Javier MD - Athira Pharma Chief Officer
| ATHA Stock | USD 0.66 0.01 1.54% |
Executive
Javier MD is Chief Officer of Athira Pharma
| Age | 59 |
| Address | 18706 North Creek Parkway, Bothell, WA, United States, 98011 |
| Phone | 425 620 8501 |
| Web | https://www.athira.com |
Athira Pharma Management Efficiency
The company has return on total asset (ROA) of (0.4753) % which means that it has lost $0.4753 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8457) %, meaning that it created substantial loss on money invested by shareholders. Athira Pharma's management efficiency ratios could be used to measure how well Athira Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of November 30, 2024, Return On Tangible Assets is expected to decline to -0.77. In addition to that, Return On Capital Employed is expected to decline to -1. At present, Athira Pharma's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 1.1 M, whereas Net Tangible Assets are forecasted to decline to about 175.1 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Steven CPA | NextCure | 61 | |
| Edward Samuel | Achilles Therapeutics PLC | N/A | |
| Chau MBA | CytomX Therapeutics | N/A | |
| Colleen Sjogren | Nuvation Bio | 54 | |
| Sebastien Maloveste | NextCure | N/A | |
| Philippe Sauvage | Nuvation Bio | 47 | |
| Sourav Kundu | NextCure | 63 | |
| Stacy Rollinger | NextCure | N/A | |
| Thomas Rollins | Assembly Biosciences | 68 | |
| Lee Stern | Achilles Therapeutics PLC | N/A | |
| Tamara LLM | Spero Therapeutics | 62 | |
| Marcia Belvin | CytomX Therapeutics | N/A | |
| Robert MBBS | Instil Bio | N/A | |
| Tariq Ahmed | Achilles Therapeutics PLC | N/A | |
| Anuj MD | Assembly Biosciences | 46 | |
| Richard Colonno | Assembly Biosciences | 74 | |
| YuWaye MD | CytomX Therapeutics | 56 | |
| Moses Makunje | Nuvation Bio | 45 | |
| Jeanette Bjorkquist | Assembly Biosciences | N/A | |
| Udayan MD | NextCure | N/A | |
| Daniel Hood | Achilles Therapeutics PLC | N/A | |
Management Performance
| Return On Equity | -0.85 | ||||
| Return On Asset | -0.48 |
Athira Pharma Leadership Team
Elected by the shareholders, the Athira Pharma's board of directors comprises two types of representatives: Athira Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Athira. The board's role is to monitor Athira Pharma's management team and ensure that shareholders' interests are well served. Athira Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Athira Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark JD, General Secretary | ||
| Samantha Willing, Executive People | ||
| Robert Renninger, Director Reporting | ||
| Dr MBA, CEO President | ||
| Kevin Church, Chief Officer | ||
| Javier MD, Chief Officer | ||
| MBA MBA, CEO Pres | ||
| Glenna Mileson, Chief Officer | ||
| Rachel MBA, Chief Officer | ||
| Julie Rathbun, Head Relations | ||
| Andrew Gengos, CFO Officer |
Athira Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Athira Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.85 | ||||
| Return On Asset | -0.48 | ||||
| Current Valuation | (42.21 M) | ||||
| Shares Outstanding | 38.67 M | ||||
| Shares Owned By Insiders | 1.95 % | ||||
| Shares Owned By Institutions | 62.13 % | ||||
| Number Of Shares Shorted | 2.22 M | ||||
| Price To Book | 0.44 X | ||||
| EBITDA | (116.7 M) | ||||
| Net Income | (117.67 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Athira Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Athira Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Athira Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Athira Pharma Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Athira Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For information on how to trade Athira Stock refer to our How to Trade Athira Stock guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Athira Pharma. If investors know Athira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Athira Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.84) | Return On Assets (0.48) | Return On Equity (0.85) |
The market value of Athira Pharma is measured differently than its book value, which is the value of Athira that is recorded on the company's balance sheet. Investors also form their own opinion of Athira Pharma's value that differs from its market value or its book value, called intrinsic value, which is Athira Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Athira Pharma's market value can be influenced by many factors that don't directly affect Athira Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Athira Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Athira Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Athira Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.